O	O	O	0	11	Suppression	Suppression	B-NP	NN	O	7	NMOD	O
O	O	O	12	14	of	of	B-PP	IN	O	1	NMOD	O
T1	B-Protein	B-Protein	15	23	TNFalpha	TNFalpha	B-NP	NN	B-protein	2	PMOD	B-protein
O	O	O	23	24	-	-	B-NP	HYPH	O	1	P	O
O	O	O	24	32	mediated	mediate	I-NP	VBN	O	7	NMOD	O
T6	B-Entity	B-Entity	33	41	NFkappaB	NFkappaB	I-NP	NN	B-protein	7	NMOD	B-protein
O	O	O	42	50	activity	activity	I-NP	NN	O	0	ROOT	O
O	O	O	51	53	by	by	B-PP	IN	O	7	NMOD	O
O	O	O	54	63	myricetin	myricetin	B-NP	NN	O	12	NMOD	O
O	O	O	64	67	and	and	O	CC	O	12	NMOD	O
O	O	O	68	73	other	other	B-NP	JJ	O	12	NMOD	O
O	O	O	74	84	flavonoids	flavonoid	I-NP	NNS	O	8	PMOD	O
O	O	O	85	92	through	through	B-PP	IN	O	7	NMOD	O
O	O	O	93	107	downregulating	downregulate	B-VP	VBG	O	13	PMOD	O
O	O	O	108	111	the	the	B-NP	DT	O	16	NMOD	O
O	O	O	112	120	activity	activity	I-NP	NN	O	14	OBJ	O
O	O	O	121	123	of	of	B-PP	IN	O	16	NMOD	O
T7	B-Entity	B-Entity	124	127	IKK	IKK	B-NP	NN	B-protein	17	PMOD	B-protein
O	O	O	128	130	in	in	B-PP	IN	O	18	NMOD	O
O	O	O	131	137	ECV304	ECV304	B-NP	NN	B-cell_line	21	NMOD	B-cell_line
O	O	O	138	143	cells	cell	I-NP	NNS	I-cell_line	19	PMOD	I-cell_line
O	O	O	143	144	.	.	O	.	O	7	P	O

O	O	O	146	156	Flavonoids	Flavonoid	B-NP	NNS	O	2	SUB	O
O	O	O	157	160	are	be	B-VP	VBP	O	19	VMOD	O
O	O	O	161	162	a	a	B-NP	DT	O	4	NMOD	O
O	O	O	163	168	group	group	I-NP	NN	O	2	PRD	O
O	O	O	169	171	of	of	B-PP	IN	O	4	NMOD	O
O	O	O	172	181	naturally	naturally	B-NP	RB	O	5	PMOD	O
O	O	O	181	182	-	-	I-NP	HYPH	O	6	P	O
O	O	O	182	191	occurring	occur	B-VP	VBG	O	6	DEP	O
O	O	O	192	200	phenolic	phenolic	B-NP	JJ	O	10	NMOD	O
O	O	O	201	210	compounds	compound	I-NP	NNS	O	8	OBJ	O
O	O	O	211	213	in	in	B-PP	IN	O	10	NMOD	O
O	O	O	214	217	the	the	B-NP	DT	O	14	NMOD	O
O	O	O	218	223	plant	plant	I-NP	NN	O	14	NMOD	O
O	O	O	224	231	kingdom	kingdom	I-NP	NN	O	11	PMOD	O
O	O	O	231	232	,	,	O	,	O	19	P	O
O	O	O	233	236	and	and	O	CC	O	19	VMOD	O
O	O	O	237	241	many	many	B-NP	JJ	O	18	NMOD	O
O	O	O	242	252	flavonoids	flavonoid	I-NP	NNS	O	19	SUB	O
O	O	O	253	256	are	be	B-VP	VBP	O	0	ROOT	O
O	O	O	257	262	found	find	I-VP	VBN	O	19	VC	O
O	O	O	263	267	with	with	B-PP	IN	O	20	VMOD	O
O	O	O	268	276	vascular	vascular	B-NP	JJ	O	24	NMOD	O
O	O	O	277	287	protective	protective	I-NP	JJ	O	24	NMOD	O
O	O	O	288	298	properties	property	I-NP	NNS	O	21	PMOD	O
O	O	O	298	299	.	.	O	.	O	19	P	O

O	O	O	300	312	Nevertheless	Nevertheless	B-ADVP	RB	O	10	VMOD	O
O	O	O	313	316	how	how	B-ADVP	WRB	O	6	DEP	O
O	O	O	317	320	the	the	B-NP	DT	O	5	NMOD	O
O	O	O	321	331	protective	protective	I-NP	JJ	O	5	NMOD	O
O	O	O	332	340	response	response	I-NP	NN	O	6	SUB	O
O	O	O	341	343	is	be	B-VP	VBZ	O	10	SUB	O
O	O	O	344	351	exerted	exert	I-VP	VBN	O	6	VC	O
O	O	O	352	354	by	by	B-PP	IN	O	7	VMOD	O
O	O	O	355	365	flavonoids	flavonoid	B-NP	NNS	O	8	PMOD	O
O	O	O	366	368	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	369	372	not	not	I-VP	RB	O	10	VMOD	O
O	O	O	373	377	well	well	I-VP	RB	O	10	VMOD	O
O	O	O	378	391	characterized	characterize	I-VP	VBN	O	10	VC	O
O	O	O	391	392	.	.	O	.	O	10	P	O

O	O	O	393	395	In	In	B-PP	IN	O	29	VMOD	O
O	O	O	396	400	view	view	B-NP	NN	O	12	SUB	O
O	O	O	401	403	of	of	B-PP	IN	O	2	NMOD	O
O	O	O	404	407	the	the	B-NP	DT	O	6	NMOD	O
T8	B-Entity	B-Entity	408	415	nuclear	nuclear	I-NP	JJ	B-protein	6	NMOD	B-protein
T8	I-Entity	I-Entity	416	422	factor	factor	I-NP	NN	I-protein	8	NMOD	I-protein
T8	I-Entity	I-Entity	422	423	-	-	O	HYPH	O	8	P	O
T8	I-Entity	I-Entity	423	429	kappaB	kappaB	B-NP	NN	B-protein	3	PMOD	B-protein
O	O	O	430	431	(	(	O	(	O	11	DEP	O
T9	B-Entity	B-Entity	431	439	NFkappaB	NFkappaB	B-NP	NN	B-protein	11	DEP	B-protein
O	O	O	439	440	)	)	O	)	O	8	NMOD	O
O	O	O	441	444	may	may	B-VP	MD	O	1	SBAR	O
O	O	O	445	449	play	play	I-VP	VB	O	12	VC	O
O	O	O	450	451	a	a	B-NP	DT	O	16	NMOD	O
O	O	O	452	459	central	central	I-NP	JJ	O	16	NMOD	O
O	O	O	460	464	role	role	I-NP	NN	O	13	OBJ	O
O	O	O	465	467	in	in	B-PP	IN	O	13	VMOD	O
O	O	O	468	471	the	the	B-NP	DT	O	19	NMOD	O
O	O	O	472	482	initiation	initiation	I-NP	NN	O	17	PMOD	O
O	O	O	483	485	of	of	B-PP	IN	O	19	NMOD	O
O	O	O	486	501	atherosclerosis	atherosclerosis	B-NP	NN	O	20	PMOD	O
O	O	O	501	502	,	,	O	,	O	29	P	O
O	O	O	503	513	prevention	prevention	B-NP	NN	O	29	SUB	O
O	O	O	514	516	of	of	B-PP	IN	O	23	NMOD	O
O	O	O	517	520	the	the	B-NP	DT	O	26	NMOD	O
O	O	O	521	531	activation	activation	I-NP	NN	O	24	PMOD	O
O	O	O	532	534	of	of	B-PP	IN	O	26	NMOD	O
T10	B-Entity	B-Entity	535	543	NFkappaB	NFkappaB	B-NP	NN	B-protein	27	PMOD	B-protein
O	O	O	544	554	represents	represent	B-VP	VBZ	O	0	ROOT	O
O	O	O	555	557	an	an	B-NP	DT	O	32	NMOD	O
O	O	O	558	567	important	important	I-NP	JJ	O	32	NMOD	O
O	O	O	568	572	role	role	I-NP	NN	O	29	OBJ	O
O	O	O	573	575	in	in	B-PP	IN	O	29	VMOD	O
O	O	O	576	586	protecting	protect	B-VP	VBG	O	33	PMOD	O
O	O	O	587	595	vascular	vascular	B-NP	JJ	O	36	NMOD	O
O	O	O	596	602	injury	injury	I-NP	NN	O	34	OBJ	O
O	O	O	602	603	.	.	O	.	O	29	P	O

O	O	O	604	606	In	In	B-PP	IN	O	32	VMOD	O
O	O	O	607	611	this	this	B-NP	DT	O	3	NMOD	O
O	O	O	612	617	study	study	I-NP	NN	O	1	PMOD	O
O	O	O	617	618	,	,	O	,	O	32	P	O
O	O	O	619	622	the	the	B-NP	DT	O	6	NMOD	O
O	O	O	623	630	effects	effect	I-NP	NNS	O	32	SUB	O
O	O	O	631	633	of	of	B-PP	IN	O	6	NMOD	O
O	O	O	634	644	flavonoids	flavonoid	B-NP	NNS	O	7	PMOD	O
O	O	O	645	647	on	on	B-PP	IN	O	6	NMOD	O
T11	B-Entity	B-Entity	648	656	NFkappaB	NFkappaB	B-NP	NN	B-protein	14	NMOD	B-protein
O	O	O	656	657	/	/	B-NP	SYM	O	14	NMOD	O
O	O	O	657	666	inhibitor	inhibitor	I-NP	NN	O	14	NMOD	O
O	O	O	666	667	-	-	B-NP	HYPH	O	14	NMOD	O
O	O	O	667	673	kappaB	kappaB	I-NP	NN	B-protein	18	NMOD	B-protein
O	O	O	674	675	(	(	O	(	O	18	NMOD	O
O	O	O	675	682	IkappaB	IkappaB	B-NP	NN	B-protein	18	NMOD	B-protein
O	O	O	682	683	)	)	O	)	O	18	NMOD	O
O	O	O	684	690	system	system	B-NP	NN	O	9	PMOD	O
O	O	O	691	693	in	in	B-PP	IN	O	18	NMOD	O
O	O	O	694	700	ECV304	ECV304	B-NP	NN	B-cell_line	21	NMOD	B-cell_line
O	O	O	701	706	cells	cell	I-NP	NNS	I-cell_line	19	PMOD	I-cell_line
O	O	O	707	716	activated	activate	B-VP	VBN	O	21	NMOD	O
O	O	O	717	721	with	with	B-PP	IN	O	22	VMOD	O
T2	B-Protein	B-Protein	722	727	tumor	tumor	B-NP	NN	B-protein	26	NMOD	B-protein
T2	I-Protein	I-Protein	728	736	necrosis	necrosis	I-NP	NN	I-protein	26	NMOD	I-protein
T2	I-Protein	I-Protein	737	743	factor	factor	I-NP	NN	I-protein	28	NMOD	I-protein
T2	I-Protein	I-Protein	743	744	-	-	O	HYPH	O	28	P	O
T2	I-Protein	I-Protein	744	749	alpha	alpha	B-NP	SYM	O	23	PMOD	O
O	O	O	750	751	(	(	O	(	O	31	DEP	O
T3	B-Protein	B-Protein	751	759	TNFalpha	TNFalpha	B-NP	NN	B-protein	31	DEP	B-protein
O	O	O	759	760	)	)	O	)	O	28	NMOD	O
O	O	O	761	765	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	766	774	examined	examine	I-VP	VBN	O	32	VC	O
O	O	O	774	775	.	.	O	.	O	32	P	O

O	O	O	776	778	We	We	B-NP	PRP	O	2	SUB	O
O	O	O	779	791	investigated	investigate	B-VP	VBD	O	0	ROOT	O
O	O	O	792	795	the	the	B-NP	DT	O	5	NMOD	O
O	O	O	796	806	inhibitory	inhibitory	I-NP	JJ	O	5	NMOD	O
O	O	O	807	813	action	action	I-NP	NN	O	2	OBJ	O
O	O	O	814	816	of	of	B-PP	IN	O	5	NMOD	O
O	O	O	817	820	six	six	B-NP	CD	O	8	NMOD	O
O	O	O	821	831	flavonoids	flavonoid	I-NP	NNS	O	6	PMOD	O
O	O	O	832	834	on	on	B-PP	IN	O	5	NMOD	O
T12	B-Entity	B-Entity	835	842	IkappaB	IkappaB	B-NP	NN	B-protein	11	NMOD	B-protein
T12	I-Entity	I-Entity	843	849	kinase	kinase	I-NP	NN	I-protein	15	NMOD	I-protein
O	O	O	850	851	(	(	O	(	O	14	DEP	O
T13	B-Entity	B-Entity	851	854	IKK	IKK	B-NP	NN	B-protein	14	DEP	B-protein
O	O	O	854	855	)	)	O	)	O	11	NMOD	O
O	O	O	856	864	activity	activity	B-NP	NN	O	18	NMOD	O
O	O	O	864	865	,	,	O	,	O	18	P	O
O	O	O	866	868	an	an	B-NP	DT	O	18	NMOD	O
O	O	O	869	875	enzyme	enzyme	I-NP	NN	O	9	PMOD	O
O	O	O	876	884	recently	recently	B-ADVP	RB	O	2	VMOD	O
O	O	O	885	890	found	find	B-VP	VBD	O	2	VMOD	O
O	O	O	891	893	to	to	I-VP	TO	O	22	VMOD	O
O	O	O	894	907	phosphorylate	phosphorylate	I-VP	VB	O	20	VMOD	O
O	O	O	908	916	critical	critical	B-NP	JJ	O	25	NMOD	O
T14,T15	B-Entity,B-Entity	B-Entity,B-Entity	917	923	serine	serine	I-NP	NN	O	25	NMOD	O
T14	I-Entity	I-Entity	924	932	residues	residue	I-NP	NNS	O	22	OBJ	O
O	O	O	933	935	of	of	B-PP	IN	O	25	NMOD	O
O	O	O	936	943	IkappaB	IkappaB	B-NP	NN	B-protein	26	PMOD	B-protein
O	O	O	944	947	for	for	B-PP	IN	O	22	VMOD	O
O	O	O	948	959	degradation	degradation	B-NP	NN	O	28	PMOD	O
O	O	O	959	960	.	.	O	.	O	2	P	O

O	O	O	961	963	Of	Of	B-PP	IN	O	7	VMOD	O
O	O	O	964	967	six	six	B-NP	CD	O	3	NMOD	O
O	O	O	968	978	flavonoids	flavonoid	I-NP	NNS	O	1	PMOD	O
O	O	O	979	985	tested	test	B-VP	VBN	O	3	NMOD	O
O	O	O	985	986	,	,	O	,	O	7	P	O
O	O	O	987	996	myricetin	myricetin	B-NP	NN	O	7	SUB	O
O	O	O	997	1000	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1001	1006	found	find	I-VP	VBN	O	7	VC	O
O	O	O	1007	1009	to	to	I-VP	TO	O	11	VMOD	O
O	O	O	1010	1018	strongly	strongly	I-VP	RB	O	11	VMOD	O
O	O	O	1019	1026	inhibit	inhibit	I-VP	VB	O	8	VMOD	O
T16	B-Entity	B-Entity	1027	1030	IKK	IKK	B-NP	NN	B-protein	14	NMOD	B-protein
O	O	O	1031	1037	kinase	kinase	I-NP	NN	I-protein	14	NMOD	I-protein
O	O	O	1038	1046	activity	activity	I-NP	NN	O	11	OBJ	O
O	O	O	1046	1047	,	,	O	,	O	11	P	O
O	O	O	1048	1051	and	and	O	CC	O	11	VMOD	O
O	O	O	1052	1059	prevent	prevent	B-VP	VBP	O	11	VMOD	O
O	O	O	1060	1063	the	the	B-NP	DT	O	19	NMOD	O
O	O	O	1064	1075	degradation	degradation	I-NP	NN	O	17	OBJ	O
O	O	O	1076	1078	of	of	B-PP	IN	O	19	NMOD	O
T4	B-Protein	B-Protein	1079	1091	IkappaBalpha	IkappaBalpha	B-NP	NN	B-protein	23	NMOD	B-protein
O	O	O	1092	1095	and	and	I-NP	CC	O	23	NMOD	O
T5	B-Protein	B-Protein	1096	1107	IkappaBbeta	IkappaBbeta	I-NP	NN	B-protein	20	PMOD	B-protein
O	O	O	1108	1110	in	in	B-PP	IN	O	17	VMOD	O
O	O	O	1111	1120	activated	activate	B-NP	VBN	B-cell_type	27	NMOD	B-cell_type
O	O	O	1121	1132	endothelial	endothelial	I-NP	JJ	I-cell_type	27	NMOD	I-cell_type
O	O	O	1133	1138	cells	cell	I-NP	NNS	I-cell_type	24	PMOD	I-cell_type
O	O	O	1138	1139	.	.	O	.	O	7	P	O

O	O	O	1140	1151	Furthermore	Furthermore	B-ADVP	RB	O	4	VMOD	O
O	O	O	1151	1152	,	,	O	,	O	4	P	O
O	O	O	1153	1162	myricetin	myricetin	B-NP	NN	O	4	SUB	O
O	O	O	1163	1166	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1167	1171	also	also	I-VP	RB	O	4	VMOD	O
O	O	O	1172	1177	found	find	I-VP	VBN	O	4	VC	O
O	O	O	1178	1180	to	to	I-VP	TO	O	8	VMOD	O
O	O	O	1181	1188	inhibit	inhibit	I-VP	VB	O	6	VMOD	O
T17	B-Entity	B-Entity	1189	1197	NFkappaB	NFkappaB	B-NP	NN	B-protein	10	NMOD	B-protein
O	O	O	1198	1206	activity	activity	I-NP	NN	O	8	OBJ	O
O	O	O	1207	1217	correlated	correlate	B-VP	VBD	O	10	NMOD	O
O	O	O	1218	1222	with	with	B-PP	IN	O	11	VMOD	O
O	O	O	1223	1234	suppression	suppression	B-NP	NN	O	12	PMOD	O
O	O	O	1235	1237	of	of	B-PP	IN	O	13	NMOD	O
O	O	O	1238	1246	monocyte	monocyte	B-NP	NN	O	16	NMOD	O
O	O	O	1247	1255	adhesion	adhesion	I-NP	NN	O	14	PMOD	O
O	O	O	1256	1258	to	to	B-PP	TO	O	16	NMOD	O
O	O	O	1259	1265	ECV304	ECV304	B-NP	NN	B-cell_line	19	NMOD	B-cell_line
O	O	O	1266	1271	cells	cell	I-NP	NNS	I-cell_line	17	PMOD	I-cell_line
O	O	O	1271	1272	.	.	O	.	O	4	P	O

O	O	O	1273	1282	Therefore	Therefore	B-ADVP	RB	O	3	VMOD	O
O	O	O	1283	1285	we	we	B-NP	PRP	O	3	SUB	O
O	O	O	1286	1294	conclude	conclude	B-VP	VBP	O	0	ROOT	O
O	O	O	1295	1299	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	O	1300	1310	flavonoids	flavonoid	B-NP	NNS	O	6	SUB	O
O	O	O	1311	1314	may	may	B-VP	MD	O	4	SBAR	O
O	O	O	1315	1317	be	be	I-VP	VB	O	6	VC	O
O	O	O	1318	1320	of	of	B-PP	IN	O	7	PRD	O
O	O	O	1321	1332	therapeutic	therapeutic	B-NP	JJ	O	10	NMOD	O
O	O	O	1333	1338	value	value	I-NP	NN	O	8	PMOD	O
O	O	O	1339	1342	for	for	B-PP	IN	O	10	NMOD	O
O	O	O	1343	1351	vascular	vascular	B-NP	JJ	O	13	NMOD	O
O	O	O	1352	1359	disease	disease	I-NP	NN	O	11	PMOD	O
O	O	O	1360	1367	through	through	B-PP	IN	O	7	VMOD	O
O	O	O	1368	1372	down	down	B-NP	JJ	O	16	NMOD	O
O	O	O	1373	1383	regulation	regulation	I-NP	NN	O	14	PMOD	O
O	O	O	1384	1386	of	of	B-PP	IN	O	16	NMOD	O
T18	B-Entity	B-Entity	1387	1395	NFkappaB	NFkappaB	B-NP	NN	B-protein	21	NMOD	B-protein
O	O	O	1395	1396	/	/	I-NP	SYM	O	21	NMOD	O
O	O	O	1396	1403	IkappaB	IkappaB	I-NP	NN	B-protein	21	NMOD	B-protein
O	O	O	1404	1410	system	system	I-NP	NN	O	17	PMOD	O
O	O	O	1410	1411	.	.	O	.	O	3	P	O

O	O	O	1412	1421	Copyright	Copyright	B-NP	NN	O	7	NMOD	O
O	O	O	1422	1426	1999	1999	I-NP	CD	O	5	NMOD	O
O	O	O	1427	1432	Wiley	Wiley	I-NP	NNP	O	5	NMOD	O
O	O	O	1432	1433	-	-	I-NP	HYPH	O	5	P	O
O	O	O	1433	1437	Liss	Liss	I-NP	NNP	O	7	NMOD	O
O	O	O	1437	1438	,	,	O	,	O	7	P	O
O	O	O	1439	1442	Inc	Inc	B-NP	NNP	O	0	ROOT	O
O	O	O	1442	1443	.	.	O	.	O	7	P	O
